NEO (NeoGenomics, Inc.) רווח נקי למניה (EPS TTM)

The change in TTM net income per share for NeoGenomics, Inc. (NEO), as seen on the GURU.Markets chart, can be attributed to the minimal impact of geopolitics on the US healthcare sector, where the latest parameter stands at -0.25. This stability is based on the deep integration of molecular tests into clinical protocols, as well as high physician confidence in the broad spectrum of genetic research provided by NeoGenomics, Inc. (NEO).
פילוחים אנליטיים ודוחות נתונים של חברת NeoGenomics Inc (NEO)

EPS TTM dynamics determine the fair value of the asset, allowing investors to assess the real profitability of each share while filtering out one-off market noise. Analyzing earnings per share over the last four quarters reveals critical drawdowns or overvaluations, which is particularly vital for NeoGenomics, Inc. (NEO) due to its strict alignment with the narrow oncology diagnostics segment and its dependence on the technological demand of clinics.